Format

Send to

Choose Destination
Expert Opin Pharmacother. 2015;16(18):2781-92. doi: 10.1517/14656566.2015.1101449. Epub 2015 Nov 11.

Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.

Author information

1
a Harvard Medical School, Beth Israel Deaconess Medical Center , Boston , MA , USA.

Abstract

INTRODUCTION:

Irritable bowel syndrome diarrhea predominant (IBS-D) is a highly prevalent GI disease, affecting nearly a third of all patients diagnosed with irritable bowel syndrome. Current treatment options are limited.

AREAS COVERED:

This review discusses the pharmacotherapeutic options for IBS-D including currently used medications, the two newly FDA approved medications, as well as emerging therapies with potential benefit in IBS-D. Particular emphasis is placed on rifaximin and eluxadoline and their possible use in IBS-D.

EXPERT OPINION:

Current pharmacological treatment of IBS-D includes loperamide, bile acid sequestrants, antispasmodics, tricyclic antidepressants, alosetron, eluxadoline and rifaximin. The latter two treatments have significantly added to the pharmacotherapeutic options for patients suffering from IBS-D.

KEYWORDS:

diarrhea; eluxadoline; irritable bowel syndrome; pharmacological treatments; rifaximin

PMID:
26558923
DOI:
10.1517/14656566.2015.1101449
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center